DOP2020000112A - Derivado de oxi-fluoropiperidina como inhibidor de quinasa - Google Patents

Derivado de oxi-fluoropiperidina como inhibidor de quinasa

Info

Publication number
DOP2020000112A
DOP2020000112A DO2020000112A DO2020000112A DOP2020000112A DO P2020000112 A DOP2020000112 A DO P2020000112A DO 2020000112 A DO2020000112 A DO 2020000112A DO 2020000112 A DO2020000112 A DO 2020000112A DO P2020000112 A DOP2020000112 A DO P2020000112A
Authority
DO
Dominican Republic
Prior art keywords
oxy
kinase inhibitor
fluoropiperidine
derivative
fluoropiperidine derivative
Prior art date
Application number
DO2020000112A
Other languages
English (en)
Inventor
Youn Kim Nam
Ah Jun Sun
Hee Lee Jun
Woo Kim In
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of DOP2020000112A publication Critical patent/DOP2020000112A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a un compuesto representado por la siguiente Fórmula Química 1, o una sal farmacéuticamente aceptable del mismo, y el compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades que se asocian con acciones inhibidoras de quinasa.
DO2020000112A 2017-12-28 2020-06-10 Derivado de oxi-fluoropiperidina como inhibidor de quinasa DOP2020000112A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170183061 2017-12-28
PCT/KR2018/016814 WO2019132562A1 (ko) 2017-12-28 2018-12-28 카이네이즈 저해제로서의 옥시-플루오로피페리딘 유도체

Publications (1)

Publication Number Publication Date
DOP2020000112A true DOP2020000112A (es) 2020-08-31

Family

ID=67067864

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000112A DOP2020000112A (es) 2017-12-28 2020-06-10 Derivado de oxi-fluoropiperidina como inhibidor de quinasa

Country Status (32)

Country Link
US (1) US11339167B2 (es)
EP (1) EP3733673B1 (es)
JP (1) JP6995428B2 (es)
KR (2) KR102318929B1 (es)
CN (1) CN111527091B (es)
AU (1) AU2018394997B2 (es)
BR (1) BR112020013141B1 (es)
CA (1) CA3084962C (es)
CL (1) CL2020001752A1 (es)
CO (1) CO2020007162A2 (es)
DO (1) DOP2020000112A (es)
EC (1) ECSP20035590A (es)
ES (1) ES2922633T3 (es)
HR (1) HRP20221043T1 (es)
HU (1) HUE059580T2 (es)
IL (1) IL275207B (es)
LT (1) LT3733673T (es)
MA (1) MA51431B1 (es)
MX (1) MX2020006799A (es)
MY (1) MY194468A (es)
NZ (1) NZ764644A (es)
PE (1) PE20201146A1 (es)
PH (1) PH12020551013A1 (es)
PL (1) PL3733673T3 (es)
PT (1) PT3733673T (es)
RS (1) RS63515B1 (es)
RU (1) RU2758370C1 (es)
SA (1) SA520412335B1 (es)
SG (1) SG11202004917UA (es)
SI (1) SI3733673T1 (es)
TN (1) TN2020000082A1 (es)
WO (1) WO2019132562A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200629A (en) 2017-08-01 2024-01-06 Theravance Biopharma R&D Ip Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
HRP20221043T1 (hr) * 2017-12-28 2022-11-11 Daewoong Pharmaceutical Co., Ltd. Derivat oksi-fluoropiperidina kao inhibitor kinaze
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
EP3914348A1 (en) 2019-01-23 2021-12-01 Theravance Biopharma R&D IP, LLC Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
CN115023428A (zh) * 2020-01-21 2022-09-06 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2021147953A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
WO2022062601A1 (zh) * 2020-09-22 2022-03-31 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
PL2975042T3 (pl) 2010-06-23 2019-07-31 Hanmi Science Co., Ltd. Nowe pochodne skondensowanych pirymidyn do hamowania aktywności kinaz tyrozynowych
CN103814030A (zh) 2011-09-22 2014-05-21 辉瑞大药厂 吡咯并嘧啶及嘌呤衍生物
RU2645672C2 (ru) 2012-08-06 2018-02-27 Ацея Байосайенсиз Инк. Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ
CN105188704B (zh) 2013-01-16 2017-09-19 西格诺药品有限公司 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
CA2902375A1 (en) 2013-03-05 2014-09-12 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
BR112016005881A2 (pt) 2013-09-18 2017-09-12 Beijing Hanmi Pharmaceutical Co Ltd composto, composição farmacêutica e uso do composto
JP6192839B2 (ja) 2013-12-05 2017-09-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド
CN105777756B (zh) 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN105732637B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
US10023579B2 (en) 2015-12-16 2018-07-17 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
MY191110A (en) 2016-06-30 2022-05-30 Daewoong Pharmaceutical Co Ltd Pyrazolopyrimidine derivatives as kinase inhibitor
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
HRP20221043T1 (hr) * 2017-12-28 2022-11-11 Daewoong Pharmaceutical Co., Ltd. Derivat oksi-fluoropiperidina kao inhibitor kinaze

Also Published As

Publication number Publication date
MA51431A (fr) 2021-04-07
ES2922633T3 (es) 2022-09-19
KR20210062618A (ko) 2021-05-31
KR102592083B1 (ko) 2023-10-20
RS63515B1 (sr) 2022-09-30
CN111527091A (zh) 2020-08-11
EP3733673A1 (en) 2020-11-04
IL275207B (en) 2022-09-01
SI3733673T1 (sl) 2022-09-30
PH12020551013A1 (en) 2021-08-16
PT3733673T (pt) 2022-07-18
RU2758370C1 (ru) 2021-10-28
KR102318929B1 (ko) 2021-10-28
PE20201146A1 (es) 2020-10-26
WO2019132562A1 (ko) 2019-07-04
PL3733673T3 (pl) 2022-09-26
JP6995428B2 (ja) 2022-01-14
MA51431B1 (fr) 2022-08-31
EP3733673B1 (en) 2022-06-29
IL275207A (en) 2020-07-30
ECSP20035590A (es) 2020-07-31
LT3733673T (lt) 2022-08-10
EP3733673A4 (en) 2021-06-09
CL2020001752A1 (es) 2020-11-27
BR112020013141A2 (pt) 2021-02-23
JP2021506818A (ja) 2021-02-22
AU2018394997B2 (en) 2021-02-04
CN111527091B (zh) 2023-03-28
HRP20221043T1 (hr) 2022-11-11
US11339167B2 (en) 2022-05-24
AU2018394997A1 (en) 2020-06-11
SG11202004917UA (en) 2020-06-29
CA3084962A1 (en) 2019-07-04
CO2020007162A2 (es) 2020-06-19
MY194468A (en) 2022-11-30
MX2020006799A (es) 2020-09-03
CA3084962C (en) 2022-08-09
KR20190080803A (ko) 2019-07-08
US20200308177A1 (en) 2020-10-01
BR112020013141B1 (pt) 2022-03-15
HUE059580T2 (hu) 2022-11-28
NZ764644A (en) 2023-06-30
SA520412335B1 (ar) 2022-09-19
TN2020000082A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
CO2020007156A2 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
DOP2020000112A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CO2019004034A2 (es) Compuesto de piridina
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
ECSP17029203A (es) Inhibidor de cinasa aurora a
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas